YBL096C Antibody

What is YBL-006 and what is its mechanism of action?

YBL-006 is a fully human monoclonal antibody that targets programmed cell death protein 1 (PD-1). It functions as an immune checkpoint inhibitor by binding to PD-1 receptors on T cells, preventing their interaction with PD-L1 and PD-L2 proteins expressed on cancer cells. This blockade prevents the inhibitory signaling that would otherwise suppress T cell activation and proliferation. By inhibiting this immune escape mechanism, YBL-006 allows T cells to properly recognize and attack cancer cells .

The antibody was discovered from Y-Biologics' proprietary library and developed as a potential therapeutic for various solid tumors. Functional assays confirm that YBL-006 effectively inhibits PD-1/PD-L1 interactions, thereby reactivating immune cells to target cancer cells .

How does YBL-006 compare to other PD-1 inhibitors in terms of structure and function?

YBL-006 is a novel human monoclonal antibody with high specificity for the PD-1 receptor. While detailed comparative structural analyses are not fully described in the available data, functional studies demonstrate that YBL-006 effectively blocks the interaction between PD-1 and its ligands (PD-L1/PD-L2).

What types of tumors has YBL-006 shown efficacy against in clinical studies?

YBL-006 has demonstrated efficacy across several tumor types in early clinical studies. In the dose escalation cohort (cohort A), responses were observed in patients with penile squamous cell carcinoma (complete response) and anal squamous cell carcinoma (partial response) .

In the dose expansion cohort (cohort B), clinical responses occurred in multiple tumor types, including:

• Gastric cancer (complete response in one patient, partial response in two patients)

• Neuroendocrine tumors/carcinomas (partial response in two patients)

• Kidney cancer (partial response in one patient)

• Nasopharyngeal cancer (partial response in one patient)

• Hurthle cell thyroid carcinoma (partial response in one patient)

These data suggest YBL-006 may have efficacy across a broad spectrum of solid tumors, consistent with the mechanism of action of PD-1 inhibition.

How does tumor microenvironment analysis correlate with YBL-006 response?

Analysis of the tumor microenvironment (TME) has emerged as a critical factor in predicting response to immune checkpoint inhibitors. For YBL-006, exploratory biomarker analyses have included AI-powered spatial analysis of tumor-infiltrating lymphocytes (TILs) using Lunit SCOPE IO, an artificial intelligence-powered whole-slide image analyzer .

While the complete details of the correlation between TME analysis and YBL-006 response are not fully elaborated in the search results, the studies indicate that inflamed immune phenotypes assessed through TIL analysis may be associated with clinical response. Additionally, tumor mutational burden-high (TMB-H) and microsatellite instability-high (MSI-H) statuses were evaluated as potential biomarkers of response .

These analytical approaches represent cutting-edge methods in immuno-oncology to identify patients most likely to benefit from PD-1 inhibition. Researchers investigating YBL-006 should consider incorporating comprehensive TME analysis, including TIL quantification and spatial distribution assessment, into their study designs to better understand determinants of response.

What biomarker strategies are most effective for predicting response to YBL-006?

Multiple biomarker strategies have been explored to predict response to YBL-006, reflecting the complex nature of immune checkpoint inhibitor efficacy. Based on the clinical study data, several approaches show promise:

• Tumor-infiltrating lymphocyte (TIL) analysis using AI-powered whole-slide image analysis

• Tumor mutational burden (TMB) assessment, with TMB-high status potentially correlating with improved response

• Microsatellite instability (MSI) testing, with MSI-high tumors typically showing enhanced responsiveness to immune checkpoint blockade

How can computational methods improve antibody design for overcoming resistance to YBL-006?

While not specific to YBL-006, recent advances in computational antibody design methods provide promising strategies for addressing resistance to PD-1 inhibitors. Computational approaches can help redesign antibodies to overcome viral escape or, by analogy, resistance mechanisms in cancer treatment .

Key computational methods include:

• Structure-based molecular dynamics simulations to model antibody-antigen interactions and identify critical binding residues

• Machine learning approaches to predict the impact of amino acid substitutions on binding affinity

• High-throughput virtual screening of antibody variants to identify those with improved target engagement

For example, researchers at Lawrence Livermore National Laboratory developed an approach that identified key amino acid substitutions to restore antibody potency against escaped viral variants. They virtually assessed mutated antibodies' binding ability by using supercomputing capabilities to perform molecular dynamics calculations, selecting just 376 candidates from a theoretical design space of over 10^17 possibilities .

Similar computational redesign strategies could potentially be applied to overcome resistance mechanisms to YBL-006 or other PD-1 inhibitors. By identifying specific amino acid changes that enhance binding to PD-1 variants or improve interaction with the binding epitope, researchers might develop next-generation versions of YBL-006 with enhanced efficacy.

What are the optimal dosing regimens for YBL-006 based on clinical trials?

The optimal dosing of YBL-006 has been explored through a systematic clinical development program. In the dose escalation phase (cohort A), a modified '3+3' design was utilized to evaluate doses of 0.5, 2, 5, and 10 mg/kg. For the dose expansion phase (cohort B), two regimens were tested:

• 200 mg administered every 2 weeks

• 300 mg administered every 3 weeks

Clinical responses were observed across these dosing schedules, with manageable safety profiles. The established dosing regimens provide flexibility in treatment schedules, which may be advantageous for patient convenience and compliance. The every-3-week schedule, if showing comparable efficacy, may be preferred in some clinical contexts to reduce treatment burden.

Researchers designing studies with YBL-006 should consider these established dosing regimens as starting points, while recognizing that optimal dosing may vary based on tumor type, patient characteristics, and combination therapy strategies.

What techniques are most reliable for assessing YBL-006 binding affinity and specificity?

While the search results don't specifically outline binding assessment methods for YBL-006, general principles of antibody characterization apply. Based on contemporary antibody research methodologies, several techniques are particularly valuable:

• Surface Plasmon Resonance (SPR) for real-time binding kinetics measurement

• Bio-Layer Interferometry (BLI) for determination of association and dissociation rates

• Enzyme-Linked Immunosorbent Assays (ELISA) for comparative binding studies

• Flow cytometry for cell-surface binding assessment

• Isothermal Titration Calorimetry (ITC) for thermodynamic binding parameters

For functional assessment, in vitro T cell activation assays measuring cytokine production (IFN-γ, IL-2) and T cell proliferation after PD-1/PD-L1 blockade are essential. Additionally, mixed lymphocyte reactions (MLRs) can assess the capacity of YBL-006 to enhance T cell responses to allogeneic stimulation.

Advanced techniques like hydrogen-deuterium exchange mass spectrometry (HDX-MS) can provide detailed mapping of the binding interface between YBL-006 and PD-1, offering insights into the structural basis of binding specificity.

What is the safety profile of YBL-006 based on clinical trials?

YBL-006 has demonstrated a manageable safety profile consistent with other PD-1 inhibitors. In clinical trials, the most commonly reported treatment-related adverse events (AEs) were:

In cohort A (dose escalation):

• Fatigue (N=3)

• Pruritus (N=2)

In cohort B (dose expansion):

• Fatigue (N=11)

• Pruritus (N=7)

• Rash (N=5)

These adverse events are consistent with the known mechanism of action of PD-1 inhibitors and reflect immune activation. The safety profile appears manageable, with no novel or unexpected toxicities reported in the available data. Detailed information on severe adverse events or immune-related adverse events was not fully elaborated in the search results but would be important considerations for researchers designing clinical studies with YBL-006.

What clinical efficacy parameters have been documented for YBL-006?

YBL-006 has demonstrated promising clinical efficacy in early-phase trials. The key efficacy parameters documented include:

In cohort A (dose escalation, N=10):

In cohort B (dose expansion, N=53):

These efficacy data are encouraging for an early-phase study and are consistent with the known effects of PD-1 inhibition. The durable responses (median duration of 11 months) are particularly noteworthy and suggest potential for long-term benefit in responding patients.

How can researchers overcome potential limitations in antibody specificity when working with YBL-006?

While specific limitations in YBL-006 specificity are not detailed in the search results, general approaches to addressing antibody specificity challenges are applicable. Recent advances in computational antibody engineering provide valuable strategies for researchers seeking to modify or optimize antibody properties .

Key approaches include:

• Computational redesign: Using structural bioinformatics and molecular dynamics simulations to identify critical binding residues and propose targeted mutations. This approach has been successfully applied to restore antibody potency against escaped viral variants and could potentially be adapted for enhancing YBL-006 specificity .

• High-throughput screening: Combining experimental and computational methods to screen large libraries of antibody variants. For example, researchers have used phage display experiments combined with computational modeling to disentangle different binding modes and design antibodies with customized specificity profiles .

• Specificity validation: Implementing rigorous validation using multiple orthogonal techniques. Multiplex assays that simultaneously assess binding to the intended target (PD-1) and potential cross-reactive proteins are particularly valuable. The principles described for SARS-CoV-2 antibody validation, involving multiple antigens and careful ROC analyses to balance sensitivity and specificity, illustrate important methodological considerations .

• Machine learning approaches: Applying machine learning to predict antibody-antigen interactions and identify optimal sequence modifications. These methods have been successfully used to identify "just a few key amino-acid substitutions necessary to restore antibody potency" .

For YBL-006 specifically, researchers might consider these approaches if they encounter specificity limitations or seek to develop variants with enhanced properties for particular applications or patient populations.

How might resistance mechanisms to YBL-006 differ from other PD-1 inhibitors?

While specific resistance mechanisms to YBL-006 are not detailed in the search results, understanding potential resistance pathways is critical for future research. Based on knowledge of resistance to other PD-1 inhibitors, several mechanisms merit investigation:

• Epitope-specific resistance: YBL-006 binds to a specific epitope on PD-1, and mutations or conformational changes in this epitope region might differentially affect YBL-006 compared to other PD-1 inhibitors.

• Alternative immune checkpoints: Upregulation of alternative immune checkpoints (LAG-3, TIM-3, VISTA) may provide compensatory immune suppression when PD-1 is blocked. The specific profile of alternative checkpoint upregulation might vary between different PD-1 inhibitors.

• Tumor microenvironment adaptation: Changes in the tumor microenvironment, including shifts in myeloid cell populations or metabolic alterations, may contribute to resistance. These adaptations could potentially differ based on the specific binding characteristics of YBL-006.

Researchers investigating resistance to YBL-006 should consider comprehensive genomic, transcriptomic, and proteomic analyses of resistant tumors compared to baseline. Spatial profiling of the tumor microenvironment before and after resistance develops would also provide valuable insights into resistance mechanisms.

What are the most promising biomarker discovery approaches for personalizing YBL-006 therapy?

Advanced biomarker discovery approaches hold promise for personalizing YBL-006 therapy. Based on current immunotherapy research trends, several approaches warrant investigation:

• Multiplex spatial profiling: Technologies that allow simultaneous assessment of multiple proteins while preserving spatial context can provide insights into immune cell interactions within the tumor microenvironment. The AI-powered spatial analysis of tumor-infiltrating lymphocytes mentioned in the YBL-006 studies represents one such approach .

• Single-cell technologies: Single-cell RNA sequencing of tumor and immune cells can identify cell-specific expression patterns and reveal rare cell populations that may influence response to YBL-006.

• Circulating biomarkers: Liquid biopsy approaches analyzing circulating tumor DNA, exosomes, or immune cell populations may provide less invasive monitoring of response and resistance.

• Multi-omics integration: Integrating genomic, transcriptomic, proteomic, and metabolomic data can provide a comprehensive view of tumor biology and immune interactions, potentially revealing novel predictive signatures.

• Functional immune assays: Ex vivo functional assays measuring T cell responses to autologous tumor cells in the presence of YBL-006 may provide personalized assessment of potential efficacy.

Researchers should consider integrated biomarker discovery approaches that combine multiple technologies to develop comprehensive predictive models for YBL-006 response.

How might next-generation antibody engineering techniques be applied to enhance YBL-006 properties?

Next-generation antibody engineering techniques offer exciting possibilities for enhancing YBL-006 or developing improved variants. Based on recent advances in the field, several approaches show particular promise:

• Computational redesign: The approach described by Lawrence Livermore National Laboratory researchers for redesigning antibodies to overcome viral escape provides a powerful template. Using supercomputing resources to perform molecular dynamics simulations and identify specific amino acid substitutions could enhance YBL-006 binding properties or address emerging resistance .

• Customized specificity profiles: Methods combining phage display experiments with biophysics-informed modeling can generate antibodies with precisely defined specificity profiles. This approach could potentially optimize YBL-006 to enhance specificity for particular PD-1 conformations or contexts .

• Bispecific adaptations: Engineering YBL-006 into bispecific formats that simultaneously target PD-1 and complementary immune targets (such as LAG-3, the target of YBL-011) could enhance efficacy through synergistic immune activation .

• Antibody-drug conjugates: Conjugating YBL-006 with cytotoxic payloads could potentially combine immune checkpoint inhibition with direct tumor cell killing.

• Fc engineering: Modifying the Fc region of YBL-006 could enhance effector functions such as antibody-dependent cellular cytotoxicity (ADCC) or extend half-life.

Researchers exploring next-generation versions of YBL-006 should consider these emerging techniques, particularly computational approaches that can efficiently screen vast design spaces to identify optimal modifications for specific clinical applications.